Form Bio and Ginkgo Bioworks collaborate to revolutionize AAV gene therapy development

By Liza Laws

- Last updated on GMT

© Getty Images
© Getty Images

Related tags Gene therapy Manufacturing CDMO Collaboration Ginkgo Bioworks Form Bio

Form Bio and Ginkgo Bioworkshave joined forces in what they call a groundbreaking partnership aimed at advancing AAV gene therapy design and development.

This collaboration integrates Ginkgo’s licensable assets and manufacturing capabilities with Form Bio’s cutting-edge AI-driven solutions for gene therapy optimization.

The partnership offers a comprehensive solution for gene therapy developers, streamlining product optimization and accelerating the journey from lab to clinic while conserving resources. By combining Form Bio's in silico solutions with Ginkgo's AAV products and services, developers can significantly reduce both the time and costs associated with therapeutic development.

Kent Wakeford, co-founder and co-CEO of Form Bio, is optimistic about the potential impact of AI in expediting preclinical development, he said: “We are now seeing that AI can reduce preclinical development time by over 30 percent, offering the potential to get life-saving treatments to patients faster and at lower costs.” Wakeford emphasized the comprehensive nature of the partnership, noting that clients will have access to a fully integrated solution for accelerated AAV therapeutic development.

Ginkgo Bioworks' CEO, Jason Kelly, underscored the significance of the collaboration, stating, “Form Bio is a pioneer in applying AI and innovative in silico techniques to AAV development, transforming how gene therapies are developed.” He highlighted the value this collaboration brings to customers seeking to leverage advances in generative AI in a cohesive manner.

Demand for streamlined development solutions

While the current collaboration focuses on gene therapy, both Form Bio a computational life sciences solutions provider, and Ginkgo Bioworks, a leader in cell programming and biosecurity platforms, possess broad capabilities across nucleic acids, delivery platforms, and therapeutic modalities. With over 2,000 gene therapies currently in development, according to ASGCT and Citeline’s Gene, Cell, + RNA Therapy Landscape Report for Q4 2023, the demand for streamlined development solutions is evident. However, significant challenges remain in designing products that meet safety, efficacy, and manufacturability standards required for clinical success.

The partnership between Form Bio and Ginkgo Bioworks represents a significant step forward in addressing these challenges, offering hope for the expedited delivery of innovative gene therapies to patients worldwide.

Form Bio offers software and AI solutions tailored for cell and gene therapy leaders, integrating data, technology, and expertise to accelerate drug development timelines from discovery to clinic.

Comprehensive services to address challenges across pharma

The Form Bio solutions provide rapid in silico characterization, prediction, simulation, and optimization of therapeutics, resulting in higher yields, enhanced safety, and shorter, more cost-effective development cycles.

With a team boasting cross-disciplinary expertise in software engineering, biology, bioinformatics, and data science, Form Bio says it collaborates closely with clients to address their most pressing challenges and strategic opportunities.

Ginkgo Bioworks says it stands as the premier horizontal platform for cell programming, offering comprehensive services to address challenges across various sectors, including food and agriculture, pharmaceuticals, and industrial and specialty chemicals.

Its biosecurity and public health unit, Concentric by Ginkgo, is actively developing a global infrastructure for biosecurity, empowering governments, communities, and public health leaders to prevent, detect, and respond effectively to a wide range of biological threats. 

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more